Please assess the completion status of the following clinical trial:

Trial Title: Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male~* Age: ≥18 years old~* Patients with primary open angle glaucoma with mild to moderate damage or ocular hypertension that were sufficiently controlled with GAAP Ofteno® (latanoprost 0.005%) within the last 60 days~* Signed Informed Consent Form~Exclusion Criteria:~* Subjects with unique eye~* Subjects with visual acuity \< 20/200~* Another kind of glaucoma disease different to primary open angle glaucoma~* corneal disturbances with impossibility to measure the intraocular pressure~* retinal alterations without control or progressive retinal disease with high risk to lost vision

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequence 1 (PRO-067) (Type: EXPERIMENTAL): study subjects will be allocated to receive PRO-067 QD for 30 days, after which they will be crossed over to the other medication (GAAP Ofteno®) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours
- Sequence 2 (GAAP Ofteno®) (Type: ACTIVE_COMPARATOR): study subjects will be allocated to receive GAAP Ofteno® QD for 30 days, after which they will be crossed over to the other medication (PRO-067) for another 30 days. The Intraocular pressure-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline.~Washout period: 21 hours

Based on this trial design, predict the completion outcome and termination type (if applicable).